Earlier detection of ovarian cancer
Ovarian cancer is one of the leading causes of mortality in women due to inadequate early stage diagnosis. Celula’s ovarian cancer test is being developed to target disease detection at a much earlier stage. Currently the disease is often detected only in its late stages, with a 5-year survival of less than 50%.
Utilizing a proprietary Integrated Diagnostic Algorithm (IDA) and other unique testing parameters, Celula’s test design aims to deliver a screening result with a high positive predictive value (PPV) for the presence of disease, and therefore an opportunity for earlier treatment.. With higher accuracy, the potential exists to decrease unnecessary surgeries that occur due to false positive test results. Such surgeries can cause patients harm and be costly to the healthcare system. With increased accuracy also would come the potential to use such a test as an aid to improving the referral of patients at high risk for ovarian cancer to the appropriate subspecialists (Gynecologic Oncologists), who can offer better treatment options that can lead to improved outcomes.